*May 2024*
Key Takeaways: In the CHRYSALIS-2 study, amivantamab plus lazertinib demonstrated significant antitumor activity, including a 51% objective response rate and durable responses, in patients with atypical EGFR-mutated advanced NSCLC, regardless of prior treatment with afatinib.
In the CHRYSALIS-2 study’s Cohort C, evaluating amivantamab (ami) plus lazertinib (laz) in atypical EGFR-mutated advanced NSCLC, including G719X, L861Q, and S768I mutations, the combination demonstrated a robust objective response rate (ORR) of 51%, with a median duration of response (DoR) not estimable (NE) and a median progression-free survival (PFS) of 19.5 months in treatment-naïve patients. Among those previously treated with afatinib, the ORR was 45%, with a median DoR of 8.9 months and a median PFS of 5.7 months, highlighting its efficacy in patients with prior TKI exposure. Safety profiles were manageable, with predominantly grade 1-2 EGFR- and MET-related toxicities, and biomarker analyses are ongoing to further characterize responses. Read more.
